· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2022 / N 3/4 Рациональная фармакотерапия острых кишечных инфекций в клинической практике Г.Б. Селиванова, Н.Г. Потешкина, А.М. Сванадзе Список литературы/References 1. World Health Organization. Fact sheets. The top 10 causes of death. Accessed 2022 Dec 12. https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death 2. Babaei A, Rafiee N, Taheri B, Sohrabi H, Mokhtarzadeh A. Recent advances in early diagnosis of viruses associated with gastroenteritis by biosensors. Biosensors (Basel). 2022;12(7):499. DOI: 10.3390/bios12070499 3. Ono A, Aoyagi K, Muraki Y, Asai Y, Tsuzuki S, Koizumi R, Azuma T, Kusama Y, Ohmagari N. Trends in healthcare visits and antimicrobial prescriptions for acute infectious diarrhea in individuals aged 65 years or younger in Japan from 2013 to 2018 based on administrative claims database: a retrospective observational study. BMC Infectious Diseases. 2021;21(1):983. DOI: 10.1186/s12879-021-06688-2 4. Graves NS. Acute gastroenteritis. Primary Care. 2013;40(3):727-741. DOI: 10.1016/j.pop.2013.05.006 5. Dickinson B, Surawicz CM. Infectious diarrhea: an overview. Current Gastroenterology Reports. 2014;16(8):399. DOI: 10.1007/s11894-014-0399-8 6. Verdu EF, Riddle MS. Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis. The American Journal of Gastroenterology. 2012;107(7):981-989. DOI: 10.1038/ajg.2012.65 7. DuPont HL. Gastrointestinal infections and the development of irritable bowel syndrome. Current Opinion in Infectious Diseases. 2011;24(5):503-508. DOI: 10.1097/QCO.0b013e32834a962d 8. Токмалаев А.К. Применение энтеросорбентов в лечение острых кишечных инфекций. Лечащий врач. 2011;5:69-74. [Tokmalayev AK. Enterosorbents in the treatment of acute intestinal infections. Lechashchiy Vrach Journal. 2011;5:69-74. (In Russ.).] 9. Захарченко С.М. Этиотропная терапия острых кишечных инфекций. Лечащий врач. 2009;2:60-63. [Zakharchenko SM. Etiotropic therapy of acute intestinal infections. Lechashchiy Vrach Journal. 2009;2:60-63. (In Russ.).] 10. Lee HJ, Park KH, Park DA, Park J, Bang BW, Lee SS, Lee EJ, Kim YJ, Hong SK, Kim YR. Prescription of antibiotics for adults with acute infectious diarrhea in Korea: a population-based study. Infection & Chemotherapy. 2019;51(3):295-304. DOI: 10.3947/ic.2019.51.3.295 11. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. The Journal of Antibiotics (Tokyo). 2014;67(9):667-670. DOI: 10.1038/ja.2014.106 12. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion. 2006;73(Suppl 1):13-27. DOI: 10.1159/000089776 13. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51(Suppl 1):36-66. DOI: 10.1159/000081990 14. Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics. 2014;39(10):1161-1168. DOI: 10.1111/apt.12735 15. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Alimentary Pharmacology & Therapeutics. 2016;43(Suppl. 1):3-10. DOI: 10.1111/apt.13434 16. Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. The Annals of Pharmacotherapy. 2007;41(2):222-228. DOI: 10.1345/aph.1H395 17. DuPont HL. Biologic properties and clinical uses of rifaximin. Expert Opinion on Pharmacotherapy. 2011;12(2):293-302. DOI: 10.1517/14656566.2011.546347 18. Schrodt C, McHugh EE, Gawinowicz MA, DuPont HL, Brown EL. Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS One. 2013;8(7):e68550. DOI: 10.1371/journal.pone.0068550 19. Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang ZD, Halpern J, Haake R, DuPont HL. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea. American Journal of Tropical Medicine and Hygiene. 2006;74(6):1060-1066. PMID: 16760520 20. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with rifaximin. World Journal of Gastroenterology. 2009;15(21):2628-2631. DOI: 10.3748/wjg.15.2628 21. Scarpellini E, Gabrielli M, Lauritano CE, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G, Gasbarrini A. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Alimentary Pharmacology & Therapeutics. 2007;25(7):781-786. DOI: 10.1111/j.1365-2036.2007.03259.x 22. Zhang Y, Feng Y, Cao B, Tian Q. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. International Journal of Clinical and Experimental Medicine. 2015;8(2):2954-2957. PMID: 25932262 23. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity – a review. Chemotherapy. 2005;51(Suppl 1):67-72. DOI: 10.1159/000081991 24. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31(5):431-455. DOI: 10.1086/651706 25. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. The American Journal of Gastroenterology. 2013;108(4):478-498; quiz 499. DOI: 10.1038/ajg.2013.4 26. Boero M, Berti E, Morgando A, Verme G. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximin vs. vancomycin. Medical Microbiology. 1990;5:74-77. 27. Rubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile-associated diarrhea: results of an open-label pilot study. Gastroenterology. Research and Practice. 2011;2011:106978. DOI: 10.1155/2011/106978 28. Garey KW, Ghantoji SS, Shah DN, Habib M, Arora V, Jiang ZD, DuPont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. The Journal of Antimicrobial Chemotherapy. 2011;66(12):2850-2855. DOI: 10.1093/jac/dkr377 29. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Alimentary Pharmacology & Therapeutics. 2013;37(1):122-128. DOI: 10.1111/apt.12111 30. Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrobial Agents and Chemotherapy. 2013;57(6):2690-2693. DOI: 10.1128/AAC.00548-13 31. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-1491. DOI: 10.1053/j.gastro.2005.11.061 32. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World Journal of Gastroenterology. 2014;20(10):2456-2469. DOI: 10.3748/wjg.v20.i10.2456 33. Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Digestive Diseases and Sciences. 2012;57(5):1321-1329. DOI: 10.1007/s10620-012-2033-7 34. Spiller R, Lam C. An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. Journal of Neurogastroenterology & Motility. 2012;18(3):258-268. DOI: 10.5056/jnm.2012.18.3.258 35. Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. European Review for Medical and Pharmacological Sciences. 2013;17(10):1314-1320. PMID: 23740443 36. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary Pharmacology & Therapeutics. 2012;36(11-12):1084-1093. DOI: 10.1111/apt.12087 37. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. The American Journal of Gastroenterology. 2006;101(2):326-333. DOI: 10.1111/j.1572-0241.2006.00458.x 38. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Annals of Internal Medicine. 2006;145(8):557-563. DOI: 10.7326/0003-4819-145-8-200610170-00004 39. Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, Corsi E, Forbes WP, Pimentel M. T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134:A-545. DOI: 10.1016/S0016-5085(08)62544-5 40. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. The New England Journal of Medicine. 2011;364(1):22-32. DOI: 10.1056/NEJMoa1004409 41. Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for irritable bowel syndrome: a meta-analysis of randomized placebo-controlled trials. Medicine (Baltimore). 2016;95(4):e2534. DOI: 10.1097/MD.0000000000002534 42. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clinical Microbiology and Infection. 2004;10(11):1009-1011. DOI: 10.1111/j.1469-0691.2004.00997.x 43. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy. 2000;46(4):253-266. DOI: 10.1159/000007297    [ Содержание выпуска N 3/4 | Выпуски журнала | Список журналов ]